|
|
|
Novabay Pharmaceuticals 
|
0.9132 0.016 (0.02%) |
01-15 16:00 |
Open: |
0.94 |
Pre close: |
0.897 |
Target:
|
1.33
|
High: |
0.948 |
Low: |
0.8691 |
Resistance:
|
1.14
1.33
|
Volume: |
4,605,832 |
Market Cap: |
38M |
Support:
|
0.82
0.62
|
|
|
|
Technical Analysis |
Moving Averages |
MA(5):
|
0.92
 |
MACD |
MACD(12,26):
|
0.07  |
MA(20): |
0.76  |
Signal(12,26,9): |
0.05  |
MA(100): |
0.72  |
Stochastic Oscillator |
%K(14,3):
|
53.51  |
MA(250): |
0.81  |
%D(3): |
64.94  |
Average Volume(K) |
3-Month: |
193261
|
52-Week |
High:
|
1.94 |
10-Days: |
459653 |
Low: |
0.24 |
RSI |
RSI(14):
|
62.84  |
Change(%): |
47.3 |
Financials, Statistics and Valuation |
EPS |
-0.361 |
Return on Equity (ttm) |
-681.2 |
Shares Out. (M) |
41.74 |
EPS Est. Current Year |
-0.470 |
Return on Assets (ttm) |
-34.0 |
Shares Float (M) |
32.52 |
EPS Est. Next Year |
-0.090 |
PEG Ratio |
0.00 |
% Held by Insiders |
41.27 |
EPS Est. Next Quarter |
-0.030 |
Qtrly Rev. Growth |
122.7 |
% Held by Institutions |
6.53 |
Forward EPS |
-0.480 |
Gross Profit (p.s.) |
0.116 |
Shares Short (K) |
515 |
Book Value (p.s.) |
0.030 |
EBITDA (p.s.) |
-0.149 |
P/E |
-2.53 |
Sales Per Share |
0.221 |
Qtrly Earnings Growth |
0.00 |
P/BV |
30.44 |
Profit Margin |
-97.79 |
Operating Cash Flow
(M) |
-4.83 |
P/S |
4.13 |
Operating Margin |
-68.19 |
Levered Free Cash Flow
(M) |
-1.75 |
P/CF |
-7.89 |
|
|
|
|
|